002932 明德生物
按盤價 
17.650 +0.750 (+4.438%)
17.650 +0.750 (+4.438%) | 2024/06 - 中期 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 1.093 | 1.196 | 90.614 | 72.648 | 54.800 |
| 總資產報酬率 ROA (%) | 0.910 | 0.904 | 66.739 | 58.353 | 45.415 |
| 投入資產回報率 ROIC (%) | 1.068 | 1.134 | 84.568 | 67.585 | 35.171 | 邊際利潤分析 |
| 銷售毛利率 (%) | 55.418 | 54.278 | 66.846 | 75.015 | 78.209 |
| 營業利潤率 (%) | 45.445 | 19.371 | 48.240 | 59.997 | 58.626 |
| 息稅前利潤/營業總收入 (%) | 40.682 | 19.356 | 47.876 | 59.674 | 57.772 |
| 淨利潤/營業總收入 (%) | 35.504 | 9.235 | 41.600 | 51.123 | 49.591 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | -85.503 | 21.010 | 118.847 | 100.883 | 99.416 |
| 價值變動淨收益/利潤總額(%) | 81.963 | 89.456 | 0.746 | 0.040 | 0.235 |
| 營業外收支淨額/利潤總額(%) | -3.533 | -3.792 | -0.068 | -0.192 | -1.002 | 償債能力分析 |
| 流動比率 (X) | 3.262 | 2.698 | 3.248 | 5.495 | 3.937 |
| 速動比率 (X) | 3.093 | 2.571 | 3.139 | 4.974 | 3.556 |
| 資產負債率 (%) | 11.607 | 14.817 | 26.349 | 16.594 | 21.853 |
| 帶息債務/全部投入資本 (%) | 1.013 | 1.131 | 6.906 | 3.398 | -- |
| 股東權益/帶息債務 (%) | 9,654.037 | 8,631.677 | 1,336.184 | 2,821.838 | 651.091 |
| 股東權益/負債合計 (%) | 732.955 | 550.562 | 268.294 | 491.842 | 353.403 |
| 利息保障倍數 (X) | -12.668 | 27.931 | -144.295 | -287.170 | -212.237 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 1,283.173 | 905.102 | 56.380 | 58.484 | 0.000 |
| 存貨周轉天數 (天) | 330.120 | 203.374 | 27.998 | 102.427 | 0.000 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 27/09/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
